Pfizer, Inc.
Carrie Northcott, PhD is the Head of Digital Sciences within the Biomeasures, Endpoints and Study Technologies (BEST), Translational Clinical Sciences (TCS) group at Pfizer, Inc. She leads a driven and diverse team that is developing, validating, and utilizing digital health technologies (DHTs) and novel digital endpoints (NDEs) for clinical trials and beyond. These DHTs and NDEs are used to further characterize diseases for patients, health care providers and scientists, as well as demonstrate drug efficacy in clinical trials. Carrie has a diverse scientific background in Pharmacology, Toxicology, and Physiology which provides her unique insight into understanding how these NDEs provide meaningful information to patients, physicians and researchers to better treat and understand diseases.
LinkedIn: www.linkedin.com/in/carrie-northcott-1b916814